• Evaluatie van de AutoDELFIA Neonatal 17alpha-OH-Progesteron kit voor de pilot-screening op het adrenogenitaal syndroom (AGS)

      Elvers LH; Loeber JG; van Duin S; Verheul FEAM; LIS; IJsselland Ziekenhuis Capelle a/d IJssel/Algemeen Klinisch Laboratorium (Rijksinstituut voor Volksgezondheid en Milieu RIVM, 1998-02-28)
      On January 1st, 1998 a pilot has started to study the possibilities for screening on congenital adrenal hyperplasia (CAH) in the Netherlands. CAH , in the Netherlands called adrenal genital syndrome (AGS), is a severe autosomal recessive illness. The pilot will take two years and will be carried out in the provinces Utrecht, Gelderland, Zeeland and Zuid-Holland. 17alpha-Hydroxyprogesterone (17OHP) will be determined with the AutoDELFIA method (Wallac Oy, Turku, Finland) in the same dried bloodspots which are collected for the PKU/CHT screening. This report describes the results of the evaluation of this method. 17OHP was measured in 993 bloodspot samples from neonates without CAH and in 14 bloodspot samples from CAH-patients. For premature infants a negative correlation was found between the 17OHP concentration and birthweight or gestational age, respectively. Decision limits, depending on birthweight and gestational age, were calculated. The recovery for 17OHP in quality control samples obtained from Centres for Disease Control and Prevention was 86 +- 7% compared with the all laboratories trimmed mean (ALTM), and 97 +- 10% compared with the amount 17OHP added to the samples. The within- and between assay coefficient of variation was 6-12% and 6-10%, respectively. Conclusion: the AutoDELFIA is a reliable method for the determination of 17OHP in dried bloodspots.<br>